ORIGINAL ARTICLE

Association of changes in histologic severity of nonalcoholic steatohepatitis and changes in patient-reported quality of life

Laura Heath1 | Paul Aveyard1,2 | Jeremy W. Tomlinson3 | Jeremy F. Cobbold4 | Dimitrios A. Koutoukidis1,2

1Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
2National Institute for Health Research (NIHR) Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
3Oxford Centre for Diabetes, Endocrinology and Metabolism, NIHR Oxford Biomedical Research Centre, University of Oxford, Churchill Hospital, Oxford, UK
4Department of Gastroenterology and Hepatology, NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK

Correspondence
Laura Heath, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, OX2 6GG, UK.
Email: laura.heath@phc.ox.ac.uk

Funding information
National Institute for Health Research, Grant/Award Number: IS-BRC-1215-20008, LH-Academic Clinical Fellowship, Guts UK and PA - Senior Investigator Award

Abstract
Nonalcoholic steatohepatitis (NASH) is a prevalent chronic disease that is associated with a spectrum of liver fibrosis and can lead to cirrhosis. Patients with NASH report lower health-related quality of life (HRQoL) than the general population. It remains uncertain how changes in histologic severity are associated with changes in HRQoL. This is a secondary analysis of the Farnesoid X Receptor Ligand Obeticholic Acid in NASH Treatment (FLINT) and Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis (PIVENS) randomized controlled trials in patients with biopsy-proven NASH. HRQoL was assessed using short form-36 at baseline and at follow-up biopsy (at 72 and 96 weeks, respectively). Adjusted linear regression models were used to examine the association between changes in liver fibrosis (primary analysis), nonalcoholic fatty liver disease (NAFLD) activity score (secondary analysis), and changes in HRQoL scores. Compared with stable fibrosis, improvement of fibrosis by at least one stage was significantly associated with improvements only in the physical function component by 1.8 points (95% confidence interval, 0.1, 3.5). Worsening of fibrosis by at least one stage was not associated with statistically significant changes in any HRQoL domain compared with stable fibrosis. Associations between HRQoL and NAFLD disease activity score in the secondary analysis were of similar magnitude. Weight loss was associated with small improvements in physical function, general health, and energy levels. Conclusion: Improvements in fibrosis stage were associated with improvements in the physical component of HRQoL, but the clinical impact was modest. As improving fibrosis may not meaningfully improve well-being, treatment for NASH will be cost effective only if it prevents long-term hepatic and cardiovascular disease.
INTRODUCTION

Nonalcoholic fatty liver disease (NAFLD) is a chronic disease that may progress to nonalcoholic steatohepatitis (NASH), a subtype of NAFLD. The global prevalence of NASH in adults is 1%–6%. NASH is strongly associated with obesity and is considered the hepatic component of the metabolic syndrome. By 2030, the prevalence of NASH is predicted to rise by 63%, with an associated 137% increase incidence of hepatocellular carcinoma and 168% of decompensated cirrhosis. Progression from NAFLD to NASH is associated with an increase in hepatic fibrosis. Fibrosis is the factor most strongly associated with long-term liver morbidity and mortality.

Patients with NASH have impaired health-related quality of life (HRQoL) compared with the general population and patients with NAFLD. Those with NASH-related cirrhosis (i.e., fibrosis stage F4) have poorer HRQoL scores than those with noncirrhotic NASH. Patients were found to experience a broad range of physical and mental symptoms, especially fatigue, abdominal symptoms, and worry. Typically, histologic severity is negatively associated with HRQoL in cross-sectional data.

There have been numerous trials examining the effectiveness of pharmacological options for NASH, some with modest effects. To date, none of these drugs have been licensed for treatment in Europe or the United States, and the disease is managed mainly by lifestyle modification. Understanding the effect pharmacological options have on measures of HRQoL scores can be an important component of the treatment approval process. Among patients with NASH, data from shorter term trials suggest that improved hepatic fibrosis stage and reduced NAFLD activity score are associated with increased HRQoL scores. However, research into whether this relationship holds over longer time periods and whether worsening of disease activity is associated with reduced HRQoL scores is limited. The aforementioned trials have also not adjusted for changes in weight, which is a potential significant confounder of such relationships because it is associated with both changes in disease activity and changes in HRQoL.

The Farnesoid X Receptor Ligand Obeticholic Acid in NASH Treatment (FLINT) and Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis (PIVENS) trials provide an opportunity to investigate this relationship further given their rich data set and primary analysis that showed no change in HRQoL between active treatment and placebo. These studies provide histologic data from liver biopsies before and after the intervention compared with placebo arms, together with data on weight change and HRQoL. The studies used short form (SF)-36, a validated HRQoL score covering physical and mental components, at the start and end of the trials. The aim of the study was to investigate the association between changes in histologic severity and HRQoL scores in patients with NASH over 1.5 to 2 years, independent of active or placebo treatments and other confounding variables. As the SF-36 contains information in different HRQoL domains, we investigated whether changes in specific HRQoL areas were associated with changes in histologic severity.

MATERIALS AND METHODS

Design and study population

This is a secondary analysis of two published, randomized, controlled trials in adults with NASH: the FLINT and PIVENS trials. The FLINT trial was a double-blinded, multicenter, randomized, controlled trial (RCT) investigating 72 weeks of obeticholic acid versus placebo on liver histology for patients with NASH. The PIVENS trial was a double-blinded, multicenter, three-armed RCT comparing 96 weeks of treatment with pioglitazone, vitamin E, or placebo on liver histology for patients with NASH but without type 2 diabetes. In the current analysis, we employ a prospective longitudinal design. Ethical approval was granted by University of Oxford, Medical Sciences Division Ethics Committee, reference R74858/RE001, on March 5, 2021.

Inclusion criteria

All participants in the FLINT and PIVENS trials who had both a baseline and follow-up evaluable biopsy were included.

Exclusion criteria

Standard exclusion criteria to trials in NASH applied in the FLINT and PIVENS trials as reported in the original publications were used in our study.

Outcomes

The primary outcomes in this analysis were regression coefficients between change in fibrosis stage and the eight components of the SF-36 score (physical function, physical limitations, pain, general health, energy, social function, emotional limitations, and emotional well-being). Secondary outcomes were the coefficients between change in the NAFLD disease activity score and the aforementioned eight components of the SF-36 score. We also investigated regression coefficients between histologic severity (both fibrosis and the NAFLD activity score) and...
changes in the SF-36 physical and SF-36 mental component summary scores.

**Statistical analysis**

The analysis followed a prespecified statistical plan (dated January 27, 2021) published ahead of the analysis in the Open Science Framework. The primary analysis used linear regression models to explore the association between changes in hepatic fibrosis and changes in HRQoL scores. Changes in fibrosis stage were coded as “improved,” “stable,” or “worsened” if there were a change of ≥−1, 0, or ≥+1 in the stage compared with baseline, respectively, as per the cutoffs for clinically meaningful disease changes in NASH clinical trials.

Following univariable analysis, all models were adjusted for sex (binary), age (continuous), baseline body mass index (BMI) (continuous), baseline fibrosis stage (continuous), baseline value of the HRQoL-dependent variable in the model, trial (PIVENS or FLINT), treatment (active or placebo), weight change (continuous), and the number of specific comorbidities (scored 0–5 for the presence of type 2 diabetes, gastrointestinal disorders, musculoskeletal or connective tissue disorders, nervous system disorders, and psychiatric disorders).

In the secondary analysis, changes in histologic severity were defined as changes in the NAFLD activity score. This change was coded as “improved,” “stable,” or “worsened” if there were a change of ≥−2, −1 to 1, or ≥+2 in the stage compared with baseline, respectively, as per the cutoffs for clinically meaningful disease changes in NASH clinical trials. The multivariable models were adjusted for the same covariates as the primary analysis with the exception of baseline NAFLD activity score instead of baseline fibrosis stage.

We also investigated changes in summary scores of the physical (physical function, physical role, pain, and general health) and mental (energy, social function, emotional role, and emotional well-being) components of SF-36 with histologic severity (both change in fibrosis stage and change in NAFLD activity score). An interaction analysis explored the moderating effect of trial arm (placebo vs. any active treatment) between weight change and NAFLD activity score. Two post hoc exploratory analyses examined whether worsened fibrosis (compared with stable or improved fibrosis) was associated with change in HRQoL and whether improved fibrosis (compared with stable or worsened fibrosis) was associated with change in HRQoL.

When HRQoL data were missing at follow-up, we employed a last observation carried forward approach because HRQoL was also measured at intermediate time points. If observations were missing at baseline, the next recorded observation was used. Sensitivity analyses on the primary analysis, first, excluded participants with no evidence of fibrosis at both baseline and end of treatment biopsy (as there was no possibility for change) and, second, excluded participants with missing HRQoL data (complete case analysis with no imputation). All analyses were conducted in Stata (version 14.2).

**RESULTS**

A total of 421 participants were included in the analysis both from the FLINT (n = 200) and PIVENS (n = 221) trials. Baseline demographics are shown in Table 1, stratified by histologic response. Participants had a mean age of 48.9 (SD, 11.8) years and a mean BMI of 34.3 (SD, 6.5) kg/m²; 37.3% of participants were men, 25.4% had a diagnosis of type 2 diabetes, and 54.4% had at least one comorbidity. Participants with worsened fibrosis were of a similar age (p = 0.96) and sex (p = 0.91) to those with improved fibrosis. There was no evidence that prevalence of type 2 diabetes (p = 0.22) or number of comorbidities (p = 0.70) differed between worsened or improved fibrosis groups. There was evidence that the percentage of participants with improved and worsened fibrosis differed significantly between trials (p = 0.039) and by whether they received an active treatment or placebo (p = 0.001).

**HRQoL at baseline**

Physical function was significantly lower at baseline among patients with worsened fibrosis at follow-up compared with those with improved fibrosis (p = 0.026; Table 1). However, there was no evidence that other baseline HRQoL scores differed between participants with worsened and improved fibrosis stage or between participants with worsened or improved NAFLD disease activity scores (all p > 0.05; Table 1; Table S1).

**Association between change in HRQoL and changes in histologic outcomes**

Compared with stable disease in adjusted analysis, improved fibrosis was significantly associated with improvements only in the aggregate SF-36 physical health component of 1.8 (95% confidence interval [CI], 0.1, 3.5) (Figure 1; Table 2). This change was likely driven by cumulative improvements in each of the subdomains of the score, primarily pain and physical limitations, although none of these was statistically significant. In contrast, worsened fibrosis was not associated with statistically significant changes in any HRQoL domain compared with stable disease.
### TABLE 1  Baseline characteristics

| Factor                      | Fibrosis Stage |     |     |     | p value b |
|-----------------------------|----------------|-----|-----|-----|-----------|
|                             | Stable a       | Worsened a | Improved a |
| n                           | 199            | 91  | 131 |
| Age (years)                 | 49.3 (12.3)    | 48.5 (11.4) | 48.6 (11.4) | 0.96     |
| Sex                         |                |     |     |     |
| Male                        | 75 (37.7%)     | 34  (37.4%) | 48  (36.6%) | 0.91     |
| Female                      | 124 (62.3%)    | 57  (62.6%) | 83  (63.4%) |
| Number of comorbidities     |                |     |     |     |
| 0                           | 101 (50.8%)    | 35  (38.5%) | 56  (42.7%) | 0.70     |
| 1                           | 59 (29.6%)     | 36  (39.6%) | 48  (36.6%) |
| 2                           | 32 (16.1%)     | 14  (15.4%) | 22  (16.8%) |
| 3                           | 3 (1.5%)       | 5   (5.5%)  | 5   (3.8%)  |
| 4                           | 3 (1.5%)       | 1   (1.1%)  | 0   (0.0%)  |
| 5                           | 1 (0.5%)       | 0   (0.0%)  | 0   (0.0%)  |
| Type 2 diabetes             | 46 (23.1%)     | 29  (31.9%) | 32  (24.4%) | 0.22     |
| Trial                       |                |     |     |     |
| PIVENS                      | 105 (52.8%)    | 40  (44.0%) | 76  (58.0%) | 0.039    |
| FLINT                       | 94 (47.2%)     | 51  (56.0%) | 55  (42.0%) |
| Active treatment            | 113 (56.8%)    | 45  (49.5%) | 93  (71.0%) | 0.001    |
| BMI (kg/m²)                 | 34.2 (6.4)     | 34.4 (6.0)  | 34.5 (6.9)  | 0.95     |
| Weight (kg)                 | 96.9 (21.2)    | 97.5 (19.9) | 97.6 (22.2) | 0.99     |
| Baseline fibrosis stage     |                |     |     |     |
| 0                           | 38 (19.1%)     | 23  (25.3%) | 0   (0.0%)  | <0.001   |
| 1                           | 63 (31.7%)     | 35  (38.5%) | 41  (31.3%) |
| 2                           | 41 (20.6%)     | 21  (23.1%) | 50  (38.2%) |
| 3                           | 53 (26.6%)     | 12  (13.2%) | 38  (29.0%) |
| 4                           | 4 (2.0%)       | 0   (0.0%)  | 2   (1.5%)  |
| Baseline NAFLD activity     |                |     |     |     |
| 2                           | 5 (2.5%)       | 1   (1.1%)  | 4   (3.1%)  | 0.014    |
| 3                           | 24 (12.1%)     | 7   (7.7%)  | 13  (9.9%)  |
| 4                           | 38 (19.1%)     | 29  (31.9%) | 25  (19.1%) |
| 5                           | 47 (23.6%)     | 25  (27.5%) | 32  (24.4%) |
| 6                           | 54 (27.1%)     | 22  (24.2%) | 23  (17.6%) |
| 7                           | 27 (13.6%)     | 6   (6.6%)  | 27  (20.6%) |
| 8                           | 4 (2.0%)       | 1   (1.1%)  | 7   (5.3%)  |
| Physical Function           | 48.0 (10.0)    | 45.4 (12.1) | 48.6 (9.0)  | 0.026    |
| Physical Limitations        | 49.1 (10.7)    | 47.2 (11.8) | 47.9 (10.8) | 0.61     |
| Pain                        | 52.1 (9.5)     | 49.5 (11.9) | 50.2 (10.4) | 0.61     |
| General health              | 44.9 (9.0)     | 41.5 (10.4) | 43.8 (9.1)  | 0.093    |
| Energy                      | 47.7 (9.6)     | 45.6 (10.4) | 47.0 (9.6)  | 0.28     |
| Social function             | 49.2 (9.7)     | 46.9 (11.3) | 49.6 (10.0) | 0.065    |
| Emotional limitations       | 49.3 (11.0)    | 47.8 (12.4) | 49.1 (11.0) | 0.40     |
| Emotional well-being        | 49.0 (10.1)    | 46.9 (11.1) | 47.7 (9.4)  | 0.58     |
| SF-36 physical              | 48.5 (9.7)     | 45.8 (11.7) | 47.8 (9.2)  | 0.15     |
| SF-36 mental                | 48.9 (10.2)    | 47.3 (10.7) | 48.4 (10.5) | 0.45     |

Note: Higher HRQoL score indicates better or less frequent symptoms.

Abbreviations: BMI, body mass index; FLINT, Farnesoid X Receptor Ligand Obeticholic Acid in NASH Treatment; NAFLD, nonalcoholic fatty liver disease; PIVENS, Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis; SF, short form.

aData show mean (SD) or n (%).

b p value comparing improved versus worsened fibrosis stage; t test for continuous variables, chi-squared test for categorical variables.
In the secondary analysis, there was evidence that emotional limitations and aggregate mental health function score worsened by \(-2.6\) (95% CI, \(-5.0, -0.1\)) and \(-2.1\) (95% CI, \(-4.1, -0.1\)) respectively, with improvements in NAFLD disease activity score. There was no evidence that worsened NAFLD disease activity score was associated with a significant change in any HRQoL domain (Figure 1; Table 2).

Baseline demographics, stratified by fibrosis stage as improved versus stable and worsened, and fibrosis stage as worsened versus stable and improved are shown in Tables S2 and S3, respectively. A post hoc exploratory analysis compared improved fibrosis with stable and worsened fibrosis, and another analysis compared worsened fibrosis with stable and improved fibrosis (Figure 2). Results were broadly similar to the primary analysis; improved fibrosis was significantly associated with improved aggregate SF-36 physical health component by 1.8 points (95% CI, 0.2, 3.5) compared to stable and worsened fibrosis. Worsened fibrosis was additionally significantly associated with worsening of pain score by \(-2.2\) points (95% CI, \(-4.3, -0.2\)) and social function score by \(-2.2\) points (95% CI, \(-4.4, -0.1\)) compared with stable and improved fibrosis.

**Weight change**

In the multivariable model of fibrosis changes, changes in weight, the only modifiable covariate, were associated with HRQoL changes. There was evidence that each 5kg of weight loss was associated with an increase in physical function of 0.8 points (95% CI, 0.2, 1.4), in general health of 0.8 points (95% CI, 0.3, 1.3), and in energy of 0.7 points (95% CI, 0.2, 1.3). There was no evidence that weight change was associated with the other HRQoL components. The same HRQoL components were significant in the NAFLD disease activity score analysis. There was no evidence of a moderating effect of trial arm (placebo vs. any active treatment) between weight change and NAFLD activity score across all HRQoL domains ($p_{interaction} > 0.05$).

**Sensitivity analysis**

Sensitivity analysis 1 (Table S4) excluded participants with no evidence of fibrosis at baseline, and end of treatment showed results broadly consistent with the main analysis.

There was evidence that worsened fibrosis was associated with worsened pain and social function. NAFLD disease activity improvements were associated with worsening in aggregate mental health score. Despite these estimates being statistically significant, the point estimates and CIs did not materially differ from the main analysis.

Consistent with the main analysis, complete case analysis (Table S5) found evidence of an association between improvements in the NAFLD score and worsening of emotional limitations and the aggregate SF-36 mental component score. The association between fibrosis improvements and improvements in the SF-36 physical component was attenuated, and no other association was statistically significant.

**DISCUSSION**

We found some evidence that modest changes in fibrosis stage or the NAFLD activity score were independently associated with statistically significant changes in HRQoL score over 1.5–2 years. The most consistent association was between improvements in fibrosis and improvements in physical function. Our sensitivity and post hoc analyses further suggested that worsening of fibrosis is associated with worsening of pain and social function.

Previous research has suggested that a conservative clinically meaningful change in HRQoL score is half the SD, which in the present study would be approximately 5 points on the SF-36 scale.[21] This would equate to a change of approximately 5 points in the current study, but the observed average change across all scores ranged between \(-2\) and \(+3\), with relatively wide CIs. Although these changes were small and unlikely to be clinically meaningful, they suggest that larger changes in histologic severity, such as from stage 3 fibrosis to stage 0 fibrosis, are necessary to observe meaningful changes in HRQoL. This is in line with analyses showing that patients with NASH cirrhosis have significantly lower HRQoL than those with earlier stage disease.[7]

Throughout the study, participants had HRQoL scores in all domains below the 1998 US population mean of 50 (SD, 10).[22] This supports previous findings that show people with NAFLD and NASH have lower HRQoL scores, in particular, poorer physical HRQoL scores, than the general population.[23,24] However, our findings contrast with previous studies that have found significant consistent changes in HRQoL scores with changes in fibrosis stage and NAFLD disease activity score.[16,25] These studies did not adjust for weight change, which may be a significant confounder in this relationship. Another analysis found that after adjusting for changes in BMI, fibrosis improvement was associated with improvements in abdominal, emotional, worry, and total components from the Chronic Liver Disease Questionnaire for NASH.[26] Consistent with our study, these changes were small and unlikely to translate to clinically meaningful outcomes.
ASSOCIATION OF CHANGES IN HISTOLOGIC SEVERITY

A

Physical Function

Physical Limitations

Pain

General Health

Worsened vs. stable
Improved vs. stable
Weight loss (per 5 kg)
Worsened vs. stable
Improved vs. stable

-5 0 5

-5 0 5

B

Energy

Social Function

Emotional Limitations

Emotional Well-Being

Worsened vs. stable
Improved vs. stable
Weight loss (per 5 kg)
Worsened vs. stable
Improved vs. stable

-5 0 5 10

-5 0 5 10

C

Change SF-36 Physical

Change SF-36 Mental

Worsened vs. stable
Improved vs. stable
Weight loss (per 5 kg)
Worsened vs. stable
Improved vs. stable

-5 0 5 10

-5 0 5 10

Fibrosis Stage  NAFLD Disease Activity Score

Fibrosis Stage  NAFLD Disease Activity Score

Fibrosis Stage  NAFLD Disease Activity Score
Health-related quality of life scores over time

| HRQoL domain          | Fibrosis improved (95% CI) | Fibrosis worsened (95% CI) | NAFLD activity score improved (95% CI) | NAFLD activity score worsened (95% CI) |
|------------------------|---------------------------|-----------------------------|----------------------------------------|----------------------------------------|
| Physical function      | 0.6 (−1.2, 2.4)           | 0.7 (−1.3, 2.7)             | −0.2 (−2.0, 1.6)                        | 2.6 (−0.4, 6.1)                        |
| Physical limitations   | 1.6 (−0.4, 3.6)           | −0.7 (−2.9, 1.6)            | 0.6 (−1.4, 2.6)                        | 2.2 (−1.5, 5.8)                        |
| Pain                   | 1.3 (−0.6, 3.2)           | −1.8 (−3.9, 0.3)            | 0.0 (−1.9, 2.0)                        | 0.8 (−2.7, 4.3)                        |
| General health         | 0.1 (−1.4, 1.5)           | −0.5 (−2.1, 1.1)            | −0.1 (−1.6, 1.3)                       | 1.9 (−0.7, 4.5)                        |
| Energy                 | 0.5 (−1.1, 2.2)           | −0.6 (−2.4, 1.3)            | −0.5 (−2.2, 1.1)                       | 2.6 (−0.4, 5.6)                        |
| Social function        | 0.8 (−1.2, 2.8)           | −2.0 (−4.2, 0.2)            | −1.0 (−3.0, 1.0)                       | 2.5 (−1.1, 6.1)                        |
| Emotional limitations  | −1.8 (−4.2, 0.6)          | −1.8 (−4.6, 0.8)            | −2.6 (−5.0, −0.1)                      | 3.1 (−1.2, 7.4)                        |
| Emotional well-being   | −0.5 (−2.3, 1.4)          | −0.2 (−2.3, 1.8)            | −1.1 (−2.9, 0.7)                       | 2.2 (−1.1, 5.5)                        |
| SF-36 physical         | 1.8 (0.1, 3.5)*           | −0.2 (−2.1, 1.7)            | 0.8 (−0.9, 2.5)                        | 1.4 (−1.7, 4.5)                        |
| SF-36 mental           | −1.2 (−3.2, 0.8)          | −1.5 (−3.7, 0.8)            | −2.1 (−4.1, −0.1)*                     | 2.8 (−0.8, 6.4)                        |

Note: Higher HRQoL score indicates better or less frequent symptoms.
Abbreviations: CI, confidence interval; HRQoL, health-related quality of life; NAFLD, nonalcoholic fatty liver disease.
*AAdjusted for baseline fibrosis stage/NAFLD activity score, baseline HRQoL score, sex, age, baseline body mass index, study, treatment, weight change, and comorbidities.
*p < 0.05.

There was some evidence that weight change was independently associated with changes in HRQoL score, notably physical function, general health, and energy. A weight loss of 5 kg was associated with an improvement (increase) of 0.7–0.8 points on the SF-36 scales for physical function, general health, and energy. This was in line with estimates on the association between changes in BMI and changes in HRQoL from weight-loss intervention trials in other settings. Existing weight-management support and services offered to patients with NASH lead to an average 3–5-kg weight loss, such as semaglutide, may lead to larger improvements in HRQoL.

These results provide context for regulators, such as the US Food and Drug Administration (FDA) and the European Medicines Agency, while they consider new agents for approval as treatment for NASH. HRQoL data are typically included in the application for approval as worsening of disease symptoms or overall HRQoL might affect the decision-making process. The FDA has not yet approved obeticholic acid for NASH after considering the balance of potential benefits and risks with the latter, including increases in low-density lipoprotein cholesterol and pruritus. Worsening of symptoms may be reflected on patient-reported HRQoL measures. Furthermore, regulators require patient-reported HRQoL measures if they are to be used to support claims in labeling. The present study suggests that substantial changes in HRQoL may not be achievable within the medium to long term unless medication leads to prevention of serious complications of NASH, such as severe liver events and cardiovascular disease; longer follow-up in trials might be necessary to observe meaningful HRQoL changes.

Strengths of this analysis include the preregistered statistical analysis plan, use of a widely validated and reliable measure for HRQoL, the histologic assessment of disease changes using the benchmark method (i.e., biopsies), the blinded and standardized assessment of liver biopsies, and the follow-up over a 1.5–2-year period in a well-defined population with moderately advanced liver disease. The data set was mostly complete, with only seven participants (six in PIVENS and one in FLINT) with missing data in their baseline questionnaire that did not meaningfully affect the estimates in sensitivity analysis. To our knowledge, this was the first analysis to consider the association between worsened (in addition to improved) fibrosis stage or NAFLD disease activity score with HRQoL outcomes.
Limitations include using a general and not disease-specific HRQoL scale. While this allows comparison of changes in HRQoL scores among other diseases or treatments, the SF-36 questionnaire may miss some symptoms specific to liver disease, such as abdominal discomfort, that are captured in other validated scales.\textsuperscript{[34,35]} It was unclear from the study protocols whether participants completed their SF-36 before or after the results of their final biopsy were disclosed. If participants were aware of their biopsy results, this could theoretically impact their final HRQoL answers. Although both studies used the SF-36 questionnaires, there were some subtle differences in the questionnaires used that resulted in a few questions being collapsed to the lowest common denominator. For example, question 18 on the FLINT SF-36 questionnaire (corresponding to question 19 on PIVENS SF-36) gave participants five options, whereas PIVENS gave six options. Some detail was lost when the PIVENS answers had to be adjusted to five possible answers. The present analysis also found unexpected associations between worsened mental health HRQoL scores and improved NAFLD activity score. It is unclear why this association was present, and although it was potentially a chance finding, future studies should investigate it further.

In conclusion, we found some evidence that improvement of liver fibrosis stage was associated with statistically but not clinically significant improvements in some HRQoL scores in patients with biopsy-proven NASH. There was some evidence that weight loss was associated with small improvements of physical function, general health, and energy levels, although again this was not at a magnitude associated with clinically meaningful results. Future trials of potential treatments need to address the longevity and HRQoL improvements that would come with preventing severe complications of NASH, such as liver events and cardiovascular disease.

ACKNOWLEDGMENTS

The PIVENS and FLINT studies were conducted by the Nonalcoholic Steatohepatitis Clinical Research Network (NASH-CRN) Investigators and supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The data from the PIVENS and FLINT studies reported here were supplied by the NIDDK Central Repositories. This manuscript was not prepared in collaboration with investigators of the PIVENS and FLINT studies and does not necessarily reflect the opinions or views of PIVENS and FLINT studies, the NASH-CRN, the NIDDK Central Repositories, or the NIDDK. The PIVENS trial was supported in part by Takeda Pharmaceuticals North America through a Cooperative Research and Development Agreement with the NIDDK. The vitamin E and matching placebo for the PIVENS trial were provided by Pharmavite through a Clinical Trial Agreement with the National Institutes of Health. The FLINT trial was supported in part by a Collaborative Research and Development Agreement between the NIDDK and Intercept Pharmaceuticals.

FUNDING INFORMATION

This study was funded by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (grant number: IS-BRC-1215–2008). PA is NIHR Senior Investigator and also funded by the Oxford and Thames Valley NIHR Applied Research Collaboration. LH is an Academic Clinical Fellow funded by the NIHR and received a grant from Guts UK. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. The views expressed are those of the authors and not necessarily those of the National Health Service, NIHR, or Department of Health and Social Care.

CONFLICTS OF INTEREST

Dimitrios Koutoukidis, Jeremy Tomlinson, Jeremy Cobbold, and Paul Aveyard have been investigators for the National Institute for Health Research. Paul Aveyard has been an investigator for the Cambridge Weight Plan and a speaker at a conference funded by Novo Nordisk. Jeremy Tomlinson has been part of the scientific advisory boards for Pfizer, Novo Nordisk, and Poxel. Jeremy Cobbold has served on advisory boards and consulted for Intercept, Novo Nordisk, and Alnylam. Laura Heath has nothing to report.

ETHICS APPROVAL STATEMENT

Ethical approval was granted by the University of Oxford, Medical Sciences Division Ethics Committee, reference R74858/RE001 on March 5, 2021.

ORCID

Laura Heath \(\text{https://orcid.org/0000-0002-1628-1981}\)
Dimitrios A. Koutoukidis \(\text{https://orcid.org/0000-0002-1955-7234}\)
REFERENCES

1. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease: meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84.
2. Polyzos SA, Kountouras J, Mantzoros CS. Obesity and non-alcoholic fatty liver disease: from pathophysiology to therapeutics. Metabolism. 2019;92:62–97.
3. Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67(1):123–33.
4. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10(6):330–44.
5. Taylor RS, Taylor RJ, Bayliss S, Hagstrom H, Nasr P, Schattenberg JM, et al. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Gastroenterology. 2020;158(6):1611–25.e12.
6. Kennedy-Martin T, Bae JP, Paczkowski R, Freeman E. Health-related quality of life burden of nonalcoholic steatohepatitis: a robust pragmatic literature review. J Patient Rep Outcomes. 2018;2:28.
7. McSweeney L, Breckons M, Fattakhova G, Oluboyede Y, Vale L, Ternet L, et al. Health-related quality of life and patient-reported outcome measures in NASH-related cirrhosis. JHEP Rep. 2020;2(3):100099.
8. Yamamura S, Nakano D, Hashida R, Tsutsumi T, Kawaguchi T, Okada M, et al. Patient-reported outcomes in patients with non-alcoholic fatty liver disease: a narrative review of Chronic Liver Disease Questionnaire-non-alcoholic fatty liver disease/non-alcoholic steatohepatitis. J Gastroenterol Hepatol. 2021;36:629–36.
9. Younossi ZM, Stepanova M, Anstee QM, Lawitz EJ, Wai-Sun Wong V, Romero-Gomez M, et al. Reduced patient-reported outcome scores associate with level of fibrosis in patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2019;17(12):2552–60.e10.
10. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, et al.; NASH Clinical Research Network. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385(9972):936–65. Erratum in: Lancet. 2015;385(9972):946.
11. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362(18):1675–85.
12. Younossi ZM, Ratziu V, Loomba R, Binns M, Anstee QM, Goodman Z, et al.; REGENERATE Study Investigators. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2019;394(10215):2184–96. Erratum in: Lancet. 2020;396(10247):312.
13. Vachiliotis I, Gouas A, Papaioannidou P, Polyzos SA. Nonalcoholic fatty liver disease: lifestyle and quality of life. Hormones (Athens). 2022;21(1):41–9.
14. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics and Research, Center for Devices and Radiological Health. Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims. 2009. Available from: https://www.fda.gov/media/77832/download. Accessed September 2021.
15. Younossi ZM, Stepanova M, Lawitz E, Charteron M, Loomba R, Myers RP, et al. Improvement of hepatic fibrosis and patient-reported outcomes in non-alcoholic steatohepatitis treated with selonsertib. Liver Int. 2018;38(10):1849–59.
16. Younossi ZM, Stepanova M, Noureddin M, Kowdley KV, Strasser SI, Kohli A, et al. Improvements of fibrosis and disease activity are associated with improvement of patient-reported outcomes in patients with advanced fibrosis due to nonalcoholic steatohepatitis. Hepatol Commun. 2021;5(7):1201–11.
17. Koutoukidis DA, Jebb SA, Tomlinson JW, Cobbold JF, Aveyard P. Association of weight changes with changes in histological features and blood markers in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2022;20:53–47.
18. Buckell J, Mei XW, Clarke P, Aveyard P, Jebb SA. Weight loss interventions on health-related quality of life in those with moderate to severe obesity: findings from an individual patient data meta-analysis of randomized trials. Obes Rev. 2021;22(11):e13317.
19. RAND Corporation. 36-Item Short Form Survey Instrument (SF-36). Available from: https://www.rand.org/healthcare/surveys_tools/mos/36-item-short-form/survey-instrument.html. Accessed September 2021.
20. Heath L, Koutoukidis D. Association of changes in disease activity and changes in patient-reported quality of life in non-alcoholic steatohepatitis (NASH). 2021. Available from: https://osf.io/bqpsj/. Accessed September 2021.
21. Sloan JA, Cella D, Hays RD. Clinical significance of patient-reported questionnaire data: another step toward consensus. J Clin Epidemiol. 2005;58(12):1217–9.
22. Maglinte QA, Hays RD, Kaplan RM. US general population norms for telephone administration of the SF-36v2. J Clin Epidemiol. 2012;65(5):497–502.
23. David K, Kowdley KV, Unalp A, Kanwal F, Brunt EM, Schwimmer JB, et al. Quality of life in adults with nonalcoholic fatty liver disease: baseline data from the Nonalcoholic Steatohepatitis Clinical Research Network. Hepatology. 2009;49(6):1904–12.
24. Assimakopoulos K, Karavazoglou K, Tsermpini EE, Diamantopoulos G, Triantos C. Quality of life in patients with nonalcoholic fatty liver disease: a systematic review. J Psychosom Res. 2018;112:73–80.
25. Younossi ZM, Stepanova M, Nader F, Loomba R, Anstee QM, Ratziu V, et al. Obeticholic acid impact on quality of life in patients with nonalcoholic steatohepatitis: REGENERATE 18-month interim analysis. Clin Gastroenterol Hepatol. 2021; in press. https://doi.org/10.1016/j.cgh.2021.07.020.
26. Mooija AF, Motehashi K, Maroij T, Shard A, Ainsworth M, Gray A, et al. A multidisciplinary approach to the management of NAFLD is associated with improvement in markers of liver and cardiometabolic health. Frontline Gastroenterol. 2019;10(4):337–46.
27. Ahern AL, Wheeler GM, Aveyard P, Boyland EJ, Halford JCG, Mander AP, et al. Extension and standard duration weight-loss programme referrals for adults in primary care (WRAP): a randomised controlled trial. Lancet. 2017;389(10085):2214–25. Erratum in: Lancet. 2017;389(10085):2192.
28. Koutoukidis DA, Koshiaris C, Henry JA, Noreik M, Morris E, Manoharan I, et al. The effect of the magnitude of weight loss on non-alcoholic fatty liver disease: a systematic review and meta-analysis. Metabolism. 2021;115:154455.
29. Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021;384(12):1113–24.
30. Gomez MR, Austin A, Fernandes J, Ladelund S, Sejling A, Shrestha I, et al. Semaglutide improves quality of life in patients with non-alcoholic steatohepatitis. 2021. Available from: https://www.postersessiononline.eu/173580348_eu/congresos/ILC2021aula-PO_231_ILC2021.pdf. Accessed September 2021.
31. Brazier JE, Harper R, Jones NM, O’Cathain A, Thomas KJ, Usherwood T, et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ. 1992;305(6846):160–4.

32. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473–83.

33. Berger D, Desai V, Janardhan S. Con: liver biopsy remains the gold standard to evaluate fibrosis in patients with nonalcoholic fatty liver disease. Clin Liver Dis (Hoboken). 2019;13(4):114–6.

34. Younossi ZM, Stepanova M, Henry L, Racila A, Lam B, Pham HT, et al. A disease-specific quality of life instrument for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: CLDQ-NAFLD. Liver Int. 2017;37(8):1209–18.

35. Younossi ZM, Stepanova M, Younossi I, Racila A. Validation of chronic liver disease questionnaire for nonalcoholic steatohepatitis in patients with biopsy-proven nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2019;17(10):2093–100 e3.

**SUPPORTING INFORMATION**

Additional supporting information can be found online in the Supporting Information section at the end of this article.

**How to cite this article:** Heath L, Aveyard P, Tomlinson JW, Cobbold JF, Koutoukidis DA. Association of changes in histologic severity of nonalcoholic steatohepatitis and changes in patient-reported quality of life. Hepatol Commun. 2022;6:2623–2633. [https://doi.org/10.1002/hep4.2044](https://doi.org/10.1002/hep4.2044)